Heart failure: Targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Heart failure (HF) is a syndrome caused by diminished heart function that arises from pathologies like hypertension, infarction, and diabetes. Neurohormonal, cardiorenal and cardiocirculatory models have been developed to explain HF but they have not provided sufficient understanding for the elaboration of therapies to conquer the syndrome. In fact, even though progress has been made in improving survival, HF remains a frequent cause of hospitalization and death. Since in most forms of HF, development of the disorder is associated with an alteration of cardiomyocyte structure, perceived as an increase in heart mass due to cell hypertrophy, effort is being directed to address hypertrophy as a therapeutic target. Here, we outline recent understanding of two gene-silencing regulatory mechanisms underlying cardiomyocyte hypertrophy, i.e., transcriptional control by HDACs, and post-transcriptional control by microRNAs.

Original languageEnglish
Pages (from-to)1643-1648
Number of pages6
JournalInternational Journal of Biochemistry and Cell Biology
Volume40
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Hypertrophy
Heart Failure
Cardiac Myocytes
Gene Silencing
Therapeutics
MicroRNAs
Infarction
Cause of Death
Hospitalization
Pathology
Medical problems
Hypertension
Genes

Keywords

  • Heart failure
  • Histone deacetylase
  • Hypertrophy
  • MicroRNA

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

@article{ed4da49b31d643e99fe2cb45c0c2eb06,
title = "Heart failure: Targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment",
abstract = "Heart failure (HF) is a syndrome caused by diminished heart function that arises from pathologies like hypertension, infarction, and diabetes. Neurohormonal, cardiorenal and cardiocirculatory models have been developed to explain HF but they have not provided sufficient understanding for the elaboration of therapies to conquer the syndrome. In fact, even though progress has been made in improving survival, HF remains a frequent cause of hospitalization and death. Since in most forms of HF, development of the disorder is associated with an alteration of cardiomyocyte structure, perceived as an increase in heart mass due to cell hypertrophy, effort is being directed to address hypertrophy as a therapeutic target. Here, we outline recent understanding of two gene-silencing regulatory mechanisms underlying cardiomyocyte hypertrophy, i.e., transcriptional control by HDACs, and post-transcriptional control by microRNAs.",
keywords = "Heart failure, Histone deacetylase, Hypertrophy, MicroRNA",
author = "Latronico, {Michael V G} and Leonardo Elia and Gianluigi Condorelli and Daniele Catalucci",
year = "2008",
doi = "10.1016/j.biocel.2008.03.002",
language = "English",
volume = "40",
pages = "1643--1648",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Heart failure

T2 - Targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment

AU - Latronico, Michael V G

AU - Elia, Leonardo

AU - Condorelli, Gianluigi

AU - Catalucci, Daniele

PY - 2008

Y1 - 2008

N2 - Heart failure (HF) is a syndrome caused by diminished heart function that arises from pathologies like hypertension, infarction, and diabetes. Neurohormonal, cardiorenal and cardiocirculatory models have been developed to explain HF but they have not provided sufficient understanding for the elaboration of therapies to conquer the syndrome. In fact, even though progress has been made in improving survival, HF remains a frequent cause of hospitalization and death. Since in most forms of HF, development of the disorder is associated with an alteration of cardiomyocyte structure, perceived as an increase in heart mass due to cell hypertrophy, effort is being directed to address hypertrophy as a therapeutic target. Here, we outline recent understanding of two gene-silencing regulatory mechanisms underlying cardiomyocyte hypertrophy, i.e., transcriptional control by HDACs, and post-transcriptional control by microRNAs.

AB - Heart failure (HF) is a syndrome caused by diminished heart function that arises from pathologies like hypertension, infarction, and diabetes. Neurohormonal, cardiorenal and cardiocirculatory models have been developed to explain HF but they have not provided sufficient understanding for the elaboration of therapies to conquer the syndrome. In fact, even though progress has been made in improving survival, HF remains a frequent cause of hospitalization and death. Since in most forms of HF, development of the disorder is associated with an alteration of cardiomyocyte structure, perceived as an increase in heart mass due to cell hypertrophy, effort is being directed to address hypertrophy as a therapeutic target. Here, we outline recent understanding of two gene-silencing regulatory mechanisms underlying cardiomyocyte hypertrophy, i.e., transcriptional control by HDACs, and post-transcriptional control by microRNAs.

KW - Heart failure

KW - Histone deacetylase

KW - Hypertrophy

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=49949152134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49949152134&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2008.03.002

DO - 10.1016/j.biocel.2008.03.002

M3 - Article

C2 - 18514564

AN - SCOPUS:49949152134

VL - 40

SP - 1643

EP - 1648

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 9

ER -